Galixir
星药科技
Galixir (星药科技) is an AI-powered drug discovery company founded in 2019 by CEO Chengtao Li, a Tsinghua Yao Class alumnus and MIT PhD in computer science and artificial intelligence . The company builds an AI drug discovery platform that applies deep learning to molecular design, synthesis planning, and drug property prediction, aiming to cut the time and cost of traditional R&D .
The company raised angel funding in 2019 led by Gaorong Capital, followed by a Pre-A round of several million US dollars in August 2020 co-led by Source Code Capital and DCM, with Morningside Capital joining and Gaorong continuing to invest . Source Code Capital has since increased its stake in subsequent rounds . In late 2020, Galixir closed additional funding in the tens of millions of US dollars led by Redpoint China and 5Y Capital, with BAI Capital, Gaorong, DCM, and Source Code Capital also participating .
Galixir's name combines "Galaxy" and "Elixir," reflecting its mission to search the vast chemical universe—where potentially druggable compounds number around 10^60—for therapeutic compounds . The company was selected for Merck China's accelerator program in November 2019 .
Related coverage: The broader AI-for-drug-discovery space has seen continued activity, including Zai Ling Bio's nearly RMB 400 million Series B+ in 2025 and XtalPi's October 2024 partnership with Janssen Biotech to license its AI platform for large-molecule drug discovery .
AI-generated — may contain errors, please verify.
Coverage
MaHui | Nearly 20 MaHui Members Named to PEDaily's 2022 Venture50
Robots, AI, and Simulation Technologies Accelerate Industrial Adoption | Rongbao · June
Technology drives industrial transformation.
MaHui | Nearly 40 MaHui Members Named to 36Kr's X·36Under36 S-Class Young Entrepreneurs List
Medtech Entrepreneurship Is a "Game for the Brave": How to Sharpen Innovation, Product, and Organizational Capabilities | Ronghui
Discussing trends in medical technology innovation and upgrading R&D team organizational management.
Source Code Capital "Tech + Bio-Med" Investment Open Day Now Accepting Applications
"The Tech + Biotech" Crossover: A New Investment Consensus on Convergent Innovation
Professional, systematic, and patient for the long haul.
Source Code Capital closes fifth RMB fund, raising over 7 billion yuan to back tech innovation and SMEs
Invest early, invest small, invest in tech
Rongbao · August | Medical Firms Accelerate Clinical Trials; New Funding for Chip, Consumer, and Overseas Expansion Companies
Make innovative technology accessible to more people.
Vertilite, a Domestic VCSEL Manufacturer, Closes Hundreds of Millions of Yuan in Series C3 Funding to Accelerate Automotive Electronics Push
Providing high-power and high-frequency VCSEL solutions for customers worldwide.
September, When Hope Will Break Through Like the Sun | 5Y News Monthly
The big news from last month.
Soluble Microneedle Technology Company Youwei Biology Completes Tens of Millions of Yuan in Series A Financing Led by Source Code Capital
Effortless, painless drug delivery through a simple patch application.
Source Code Capital's Xingshi Wang and Yungang Huang Named MVIP Young Investors of the Year and Best Digital Healthcare Investor
MVIP of the Year, Best Investor in Digital Healthcare.
Source Code Capital portfolio company "Lingkong Tianxing" announces completion of over 300 million yuan Series A funding round, with existing shareholder Source Code Capital continuing to increase its stake
The only high-tech enterprise in China engaged in commercial hypersonic flight technology.
Chemical.AI, an intelligent chemical synthesis platform, announced the completion of a nearly $15 million Series A+ funding round led by Source Code Capital.
Dedicated to solving new drug synthesis problems through artificial intelligence and chemical big data
Source Code Capital portfolio company Silicon Integrated announced the completion of a Series C financing round of several hundred million yuan. Source Code Capital was an investor in the company's Series B round.
Secured strategic investments from three major smartphone brands
Source Code Capital portfolio company Galixir announced the completion of a new funding round, with existing shareholder Source Code Capital continuing to increase its stake.
Continuously exploring the application of AI technology to empower innovative drug R&D
5Y News | Galixir Completes New Strategic Funding Round, Continues Advancing Drug R&D Pipeline
5Y Capital continues to watch for opportunities where information technology can be applied in healthcare and medicine.
5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
5Y Capital's Xu Tian Jing: Why We're Bullish on Digital Pharmaceutical R&D | 5Y Talk
The ITBT track has a promising future ahead.
Source Code Capital portfolio company "Julive" announces completion of RMB 400 million Series C+ funding round, with existing shareholder Source Code Capital continuing to increase its stake
Operations span seven major urban clusters across 37 cities, having served more than 3 million households in total.
Source Code Capital portfolio company "Zoneneng United" announces completion of Series C with cumulative fundraising of RMB 3 billion; existing shareholder Source Code Capital continues to increase its stake
"The Zhongneng Model" — Powering Intelligent Transformation in the Construction Machinery Industry.
No-code platform QingFlow announces completion of tens of millions of RMB in Series A+ funding; existing investor Source Code Capital continues to increase its stake
Already serving more than 200,000 enterprises, government agencies, and schools across dozens of industries, both at home and abroad.
Source Code Capital portfolio company "MOODY" announced the completion of 380 million yuan in Series B and B+ funding, with existing shareholder Source Code Capital continuing to increase its stake.
Within three months of its founding, the company launched on Tmall and broke RMB 200 million in transaction volume in its first year.
Rongbao · January | E-commerce and Retail Players Build Out Origin-Region Supply Chains; Multiple Chip, AI, and Enterprise Service Firms Close New Funding Rounds
Discover and accompany creators of a beautiful life.
Galixir's Chengtao Li: Using AI to Find the 'Key' to Curing Diseases in the Universe of Compounds | Ronghui
How artificial intelligence technology is accelerating drug discovery and development.
Source Code Capital Portfolio Company Baibu Closes $110 Million Series D+ Round, Source Code Capital Continues to Increase Stake From Angel Round Onward
Its portfolio includes business platforms such as Baibu, Quanbu, and Feisuo Zhizao, forming a vertically integrated digital service platform for the textile and apparel industry.
Gaorong Bulletin · December | Multiple Gaorong Ventures Portfolio Companies Secure New Funding in Chips, Robotics, AI Drug Discovery, New Brands, and Other Sectors
Stepping into 2021.
Galixir, a Source Code Capital portfolio company, raises tens of millions of dollars in funding, with existing investor Source Code Capital continuing to increase its stake
Galixir's technical capabilities are built on sophisticated AI models, enabling end-to-end coverage of drug discovery from hit compounds to preclinical candidates.
Galixir Announces Tens of Millions of Dollars in Funding, Using "AI+" to Break Through Bottlenecks in Drug Discovery
Gaorong Ventures led Galixir's angel round and continued to increase its stake in subsequent funding rounds.
5Y News | Galixir Announces Completion of Tens of Millions of USD in Funding, with Continued Backing from 5Y Capital
Breaking the Bottleneck in New Drug R&D with "AI+"
Source Code Capital Portfolio Company Cyclone Robotics Closes Nearly $40 Million Series B Round, Source Code Capital Continues to Increase Stake
Already serving hundreds of domestic clients across financial services, government, energy, and high-tech sectors.
Automotive parts supply chain company "Gandu Auto Parts" announced the completion of a seed and angel round totaling tens of millions of RMB, with Source Code Capital leading the angel round.
Over 100 international top-tier full-vehicle parts distributors and brand owners have joined the platform, with total SKUs exceeding 5 million.
Source Code Capital portfolio company "Ruigu Mall" announces completion of hundreds of millions of RMB in Series C2 funding; existing shareholder Source Code Capital continues to increase its stake
Covering nearly 100,000 end-customer locations across dozens of cities, with hundreds of thousands of electromechanical tools and hardware products delivered daily.
5Y Capital's Xutian Jing: ITBT Sector Has a Promising Future, Poised to Produce a New Breed of Pharma Companies with Strong Cash-Generation Capabilities | Light View
ITBT is a long game, but when it succeeds, its contribution to human society is immense.
What were the big moments for us last month? | Light Moments August Report
IPOs, Funding, Strategic Partnerships, Awards... August in Review
Gaorong Monthly · August | Waterdrop Completes $230 Million Series D Funding; Gaorong Ventures Named Among 36Kr's "Top 5 Most GP-Trusted VC Firms by LPs"
Shuidi, Kaikeba, and other companies closed major funding rounds, while Gaorong Ventures received multiple industry honors.
HAI ROBOTICS, a logistics and warehousing robotics technology company, announced it has completed a financing round exceeding 100 million yuan, led by Source Code Capital in its Series B.
It has been deployed across 3PL, footwear and apparel, e-commerce, electronics, electric power, manufacturing, pharmaceuticals, and other industries.
The Collision of AI and Pharmaceuticals: Galaxy Pharma Tech Raises Nearly $10 Million in Funding | Light Moments
Galixir announced the completion of a nearly $10 million Pre-A funding round. The round was co-led by Source Code Capital and DCM, with 5Y Capital participating as a follow-on investor. Gaorong Capital, the lead investor in the company's angel round, continued to increase its stake.
AI-assisted drug discovery company Galixir announced the completion of a Pre-A funding round of several million US dollars, co-led by Source Code Capital.
J&T Global Express has completed the development of drug discovery modules including retrosynthesis reaction prediction, drug screening, and molecular design.
